Medical devices, healthcare technology and the business of care
PMA approval · P240024

Genio System 2.1

Nyxoah S.A. · Decision date Aug 8, 2025

FDA DECISIONP240024

What did the FDA approve?

FDA records P240024 as an original PMA application. The recorded decision is approval, dated Aug 8, 2025.

FDA approval order statement

Approval for The Nyxoah Genio System 2.1, which includes the Implantable Stimulator Model #2954, Surgical Template, External Stimulator, Disposable Patch, Activation Chip Model #2364, Charging Unit Model #2238, Sleep Lab Application, Repeater, and Smartphone Application. It is indicated for use in the treatment of moderate to severe Obstructive Sleep Apnea (OSA) (apnea-hypopnea index [AHI] of greater than or equal to 15 and less than or equal to 65). The device is intended for adult patients 22 years of age and older who have been confirmed to fail, cannot tolerate or are ineligible to be treated with current standard of care treatments including lifestyle modifications, positive airway pressure (PAP) treatments (such as continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BiPAP] machines), oral appliances (such as mandibular advancement devices), and pharmacotherapy (such as tirzepatide). PAP failure is defined as an inability to eliminate OSA (residual AHI of greater than 15 despite PAP usage), and PAP intolerance is defined as: 1. Inability to use PAP (at least 5 nights per week of usage; usage defined as greater than 4 hours of use per night), or 2. Unwillingness to use PAP (PAP therapy initiated and subsequently discontinued by choice).
Regulatory pathway
Original PMA
Clinical specialty
Anesthesiology
Decision date
Aug 8, 2025

FDA source record

Regulatory record facts

Identifier
P240024
Regulatory pathway
Premarket approval application
Applicant
Nyxoah S.A.
Product code
MNQ
Decision code
APPR
Decision date
Aug 8, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, hypoglossal nerve, implanted, apnea.

Applicant
Nyxoah S.A.
Product code
MNQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240024 received

    Application receipt date recorded by FDA.

  2. P240024 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P240024. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240024

Product / regulatory recordCompanyPathwayDecision dateSource
Genio System 2.1P240024/S001
Nyxoah S.A.PMA supplementOct 3, 2025FDA
Genio System 2.1P240024/S002
Nyxoah S.A.PMA supplementNov 6, 2025FDA
Genio System 2.1P240024/S003
Nyxoah S.A.PMA supplementJun 8, 2026FDA
Genio System 2.1P240024/S004
Nyxoah S.A.PMA supplementJul 30, 2026FDA

Explore the linked device profile

Other records with product code MNQ

Product / regulatory recordCompanyPathwayDecision dateSource
Inspire Medical SystemsPMA supplementNov 5, 2026FDA
Inspire Medical SystemsPMA supplementOct 26, 2026FDA
Model 3150 IPGP130008/S147
Inspire Medical SystemsPMA supplementOct 22, 2026FDA
Model 3150 IPGP130008/S146
Inspire Medical SystemsPMA supplementOct 13, 2026FDA
Inspire Medical SystemsPMA supplementAug 28, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Nyxoah S.A.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Rue Edouard Belin, 12, Mont-Saint-Guibert, 1435

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records